Page 126 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman

Chapter 6
References
1. Munk AC, Gudlaugsson E, Ovestad IT, Lovslett K, Fiane B, Hidle B, et al. Interaction of epithelial biomarkers, local immune response and condom use in cervical intraepithelial neoplasia 2-3 regression. Gynecol Oncol. 2012;127(3):489-94.
2. Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, Elko A, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res. 2005;11(13):4717-23.
3. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999;91(3):252-8.
4. Discacciati MG, de Souza CA, d’Otavianno MG, Angelo-Andrade LA, Westin MC, Rabelo- Santos SH, et al. Outcome of expectant management of cervical intraepithelial neoplasia grade 2 in women followed for 12 months. Eur J Obstet Gynecol Reprod Biol. 2011;155(2):204- 8.
5. Moore K, Cofer A, Elliot L, Lanneau G, Walker J, Gold MA. Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol. 2007;197(2):141 e1-6.
6. Lee MH, Finlayson SJ, Gukova K, Hanley G, Miller D, Sadownik LA. Outcomes of Conservative Management of High Grade Squamous Intraepithelial Lesions in Young Women. J Low Genit Tract Dis. 2018;22(3):212-8.
7. Kyrgiou M, Athanasiou A, Kalliala IEJ, Paraskevaidi M, Mitra A, Martin-Hirsch PP, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev. 2017;11:CD012847.
8. Group T, Sharp L, Cotton S, Cochran C, Gray N, Little J, et al. After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial. BJOG. 2009;116(11):1506-14.
9. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S1-S27.
10. Ho GY, Einstein MH, Romney SL, Kadish AS, Abadi M, Mikhail M, et al. Risk factors for persistent cervical intraepithelial neoplasia grades 1 and 2: managed by watchful waiting. J Low Genit Tract Dis. 2011;15(4):268-75.
11. Munk AC, Gudlaugsson E, Malpica A, Fiane B, Lovslett KI, Kruse AJ, et al. Consistent condom use increases the regression rate of cervical intraepithelial neoplasia 2-3. PLoS One. 2012;7(9):e45114.
12. Sole-Sedeno JM, Mancebo G, Miralpeix E, Lloveras B, Bellosillo B, Alameda F, et al. Utility of Human Papillomavirus Genotyping in the Management of Low-Grade Squamous Intraepithelial Lesions. J Low Genit Tract Dis. 2018;22(1):13-6.
13. Koeneman MM, Kruitwagen RF, Nijman HW, Slangen BF, Van Gorp T, Kruse AJ. Natural history of high-grade cervical intraepithelial neoplasia: a review of prognostic biomarkers. Expert Rev Mol Diagn. 2015;15(4):527-46.
14. Loopik DL, Doucette S, Bekkers RL, Bentley JR. Regression and Progression Predictors of CIN2 in Women Younger Than 25 Years. J Low Genit Tract Dis. 2016;20(3):213-7.
124